Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07805681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma

Name: Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma — clinical trial record (NCT07805681)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASSURE

StatusNot Yet Recruiting

PhaseNot specified

SponsorImmunovia, Inc.

Started2026-09

View on ClinicalTrials.gov ↗

The goal of this observational registry is to examine the changes made to pancreatic cancer surveillance management following the real-world clinical use of PancreaSure testing among individuals at increased risk for pancreatic ductal adenocarcinoma. The main question it aims to answer is, does surveillance management and intent change following the return of PancreaSure binary results.

Trial Details

NCT Number	NCT07805681
Lead Sponsor	Immunovia, Inc.
Conditions	PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Cancer Diagnosis
Enrollment	400 participants
Start Date	2026-09
Primary Completion	2028-01 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-09-04